Cystic Fibrosis (CF) – Epidemiology Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Cystic fibrosis (CF) is a progressive, inherited disorder that primarily affects the respiratory and digestive systems. In people with CF, mucus, sweat, and other fluids produced in these systems are sticky and thick, and may obstruct the passageways in the lungs and pancreas (Mayo Clinic, 2021). Mucus build-up and airway blockages in the lungs cause symptoms such as persistent cough, wheezing, inflamed nasal passages, and recurrent lung infections. Impacts on the digestive system can lead to chronic constipation, intestinal blockages, and weight loss (Mayo Clinic, 2021).

GlobalData epidemiologists utilized comprehensive, country-specific data from national CF registries and peer-reviewed journal articles to arrive at a meaningful, in-depth analysis and forecast for the diagnosed prevalent cases of CF. For all the 7MM, CF cases were segmented by age, sex, mutation type, and MRSA infection. Finally, historical data were evaluated in all 7MM to strengthen the forecast by more accurately capturing changes in prevalence throughout the forecast period.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of CF in the 7MM will grow by an annual growth rate (AGR) of 0.51% over the next 10 years, from 69,134 cases in 2020 to 72,659 cases in 2030. For CF mutation type in 2020, the F508del was the most prevalent gene mutation, representing 80.51% of diagnosed prevalent cases of CF in the 7MM. With the more widespread implementation of newborn screening programs, CF is now detected, and thus intervention can begin, earlier than ever. GlobalData epidemiologists expect that continued improvements in the treatment and care of CF patients may drive the number of diagnosed prevalent cases higher as people with CF live longer.

Scope

The Cystic Fibrosis Epidemiology Report and Model provide an overview of the risk factors, comorbidities, and global trends of Cystic Fibrosis (CF) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada).

The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of CF segmented by age (0-1, 2-5, 6-11, 12-17, 18-29 years, and by 10-year age groups up to 80 years and older) and sex. Diagnosed prevalent cases of CF are further segmented by specific mutation type and chronic methicillin-resistant Staphylococcus aureus (MRSA) infection. The epidemiology model corresponding to this report further provides the diagnosed prevalent cases of CF segmented by Pseudomonas aeruginosa infection and presence of exocrine pancreatic insufficiency.

The CF epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

The CF Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CF markets.

Quantify patient populations in the global CF markets to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.

Understand magnitude of the CF population by age, sex, mutation type, and MRSA infection.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Cystic Fibrosis: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.3.1 Registry-Based Diagnosed Prevalence of CF

2.3.2 Registry-Based Diagnosed Prevalent Cases Adjusted for Underestimation

2.4 Forecast Methodology

2.4.1 Sources

2.4.2 Sources Not Used

2.4.3 Forecast Assumptions and Methods

2.4.4 Registry-Based Diagnosed Prevalent Cases of CF

2.4.5 Registry-Based Diagnosed Prevalent Cases of CF by Specific Mutation

2.4.6 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection

2.4.7 Registry-Based Diagnosed Prevalent Cases Adjusted for Underestimation

2.5 Epidemiological Forecast for CF (2020–2030)

2.5.1 Registry-Based Diagnosed Prevalent Cases of CF

2.5.2 Age-Specific Registry-Based Diagnosed Prevalent Cases of CF

2.5.3 Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF

2.5.4 Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations

2.5.5 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection

2.5.6 Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation

2.5.7 Age-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation

2.5.8 Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation

2.5.9 Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations Adjusted for Underestimation

2.5.10 Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection Adjusted for Underestimation

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of Analysis

2.6.4 Strengths of Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

3.3 Contact Us

Table

Table 1: Summary of Updated Data Types, Registry-Based Forecast

Table 2: Summary of Updated Data Types, Registry-Based Forecast Adjusted for Underestimation

Table 3: Risk Factors and Comorbidities for CF

Figures

Figure 1: 7MM, Registry-Based Diagnosed Prevalent Cases of CF, Both Sexes, All Ages, 2020 and 2030

Figure 2: 7MM, Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, Both Sexes, All Ages, 2020 and 2030

Figure 3: 7MM, Registry-Based Diagnosed Prevalence of CF, Men and Women, All Ages, 2010–2030 (%)

Figure 4: 7MM, Registry-Based Diagnosed Prevalence of CF Adjusted for Underestimation, Men and Women, All Ages, 2010–2030 (%)

Figure 5: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF

Figure 6: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF by Specific Mutation

Figure 7: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection

Figure 8: Sources Used for Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation

Figure 9: Registry-Based Diagnosed Prevalent Cases of CF, 7MM, Men and Women, All Ages, 2020

Figure 10: 7MM, Age-Specific Registry-Based Diagnosed Prevalent Cases of CF, Men and Women, 2020 (N)

Figure 11: 7MM, Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF, All Ages, 2020 (N)

Figure 12: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Specific Mutations, Men and Women, All Ages, 2020 (N)

Figure 13: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Men and Women, All Ages, 2020 (N)

Figure 14: Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, 7MM, Men and Women, All Ages, 2020

Figure 15: 7MM, Age-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, Men and Women, 2020 (N)

Figure 16: 7MM, Sex-Specific Registry-Based Diagnosed Prevalent Cases of CF Adjusted for Underestimation, All Ages, 2020 (N)

Figure 17: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Mutations Adjusted for Underestimation, Men and Women, All Ages, 2020 (N)

Figure 18: 7MM, Registry-Based Diagnosed Prevalent Cases of CF with Chronic MRSA Infection Adjusted for Underestimation, Men and Women, All Ages, 2020 (N)

Frequently asked questions

Cystic Fibrosis (CF) – Epidemiology Forecast to 2030 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Cystic Fibrosis (CF) – Epidemiology Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cystic Fibrosis (CF) – Epidemiology Forecast to 2030 in real time.

  • Access a live Cystic Fibrosis (CF) – Epidemiology Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.